摘要
目的：观察乌梅汤治疗肠易激综合征（IBS）脾胃虚弱证的临床疗效及其对血浆P物质（SP）、降钙素基因相关肽（CGRP）水平的影响,初步探讨其作用机制。方法：腹泻型IBS患者90例,随机分为观察组60例、对照组30例。观察组应用乌梅汤治疗,对照组应用枸橼酸莫沙必利胶囊治疗,2组均以治疗4W为1疗程。结果：乌梅汤治疗腹泻型IBS总有效率为90.0%,明显优于对照组之70.0%（P〈0.05）;治疗后2组患者血浆SP、CGRP水平均明显降低,与治疗前比较,差异具有显著性（P〈0.05~0.01）;观察组效果更明显,与对照组治疗后比较,有显著性差异（（P〈0.05）。结论：乌梅汤治疗腹泻型IBS的作用机制可能是通过降低血浆SP、CGRP水平实现的。
Objective： To observe therapeutic effect of Wumei Tang on irritable bowel syndrome with spleen and stomach weak patients and effects on the levels of serum P（ SP） and calcitonin gene related peptide（ CGRP）,preliminary explore its action mechanism. Methods： 90 cases of diarrhea type of IBS patients were randomly divided into observation group（ 60 cases）,and control group（ 30 cases）,control group was given Mosa-pride Citrate,observation group was given Wumei Tang,4 weeks was one treatment course. Plasma SP and CGRP levels were determined by RIA. Results： The total effec-tive rate of observation group was 90. 0%,that was significant better than that of control（ P〈0. 05）. The plasma SP and CGRP levels were decreased significantly in the two groups after treatment,the difference were significant to compare with before treatment; the effects of Wumei Tang group was more obvious than that of control group（ P〈0. 05）. Conclusion： Wumei Tang can effectively treat IBS,reducing SP and CGRP levels was the part mechanism.
出处
《中国中医药科技》
CAS
2016年第5期515-517,共3页
Chinese Journal of Traditional Medical Science and Technology
基金
山东省济宁市中医药科技发展计划项目(zk201307)
关键词
结肠疾病
功能性
脾胃虚弱
乌梅汤
降钙素基因相关肽
@血浆P物质
人类
colonic disease
functional
spleen and stomach weak
Wumei Tang
calcionin gene related peptide（CGRP）
serum P substance（SP）
human being
